Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley

3 weeks ago 19

TipRanks

Thu, February 26, 2026 astatine 7:35 AM CST 1 min read

B. Riley raised the firm’s price target connected Vanda Pharmaceuticals (VNDA) to $17 from $14 and keeps a Buy standing connected the shares. Following BYSANTI’s approval, the firm’s gross exemplary for Vanda has been updated, reflecting expected maturation successful the psychiatry franchise with highest BYSANTI income present included and probability adjustments removed, the expert tells investors successful a probe note. Base assumptions see mid-to-high single-digit 4th implicit 4th maturation successful BYSANTI/FANAPT prescriptions done 2026, the steadfast says.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected VNDA:

Disclaimer & DisclosureReport an Issue

Vanda announces FDA accepted BLA for imsidolimab
Midday Fly By: Trump ups worldwide tariff to 15%, Gilead buying Arcellx
Unusually progressive enactment classes connected unfastened February 23rd
Largest get complaint increases among liquid names
Vanda Wins FDA Approval for Bysanti Antipsychotic Therapy

Read Entire Article